Damora Therapeutics Quarterly Income Statement
NASDAQ: DMRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
21.08+0.52 (+2.53%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Damora Therapeutics revenue and earnings
Damora Therapeutics reported a net loss of $31.2 million, compared with a loss of $3.4 million a year earlier. Diluted earnings per share came in at -$0.39.
Summary generated from market data by MetaCap's automated system. Methodology
Damora Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 34.99M | 30.81M | 201.70M | 3.16M | 3.42M | 2.60M | 7.10M | 3.84M | 5.58M | 5.74M | 6.67M | 8.58M |
| Research & Development | 25.54M | 23.78M | 23.32M | 1.42M | 1.47M | 678.00K | 1.01M | 1.09M | 1.83M | 2.46M | 2.77M | 2.55M |
| Operating Income | -34.99M | -30.81M | -201.70M | -3.16M | -3.42M | -2.60M | -7.10M | -3.84M | -5.58M | -5.74M | -6.67M | -8.58M |
| Other Income (Expense) | 4.08M | 3.07M | 1.00M | 23.00K | -12.00K | 68.00K | 353.00K | -36.00K | 281.00K | 264.00K | 196.00K | 447.00K |
| Pretax Income | -30.92M | -27.74M | -200.69M | -3.13M | -3.43M | -2.53M | -6.75M | -3.88M | -5.30M | -5.48M | -6.47M | -8.14M |
| Income Tax | 255.00K | 42.00K | 44.00K | 0 | 4.00K | 2.00K | -8.00K | 7.00K | 42.00K | — | — | — |
| Net Income | -31.17M | -27.78M | -200.74M | -3.13M | -3.44M | -2.53M | -6.74M | -3.88M | -5.34M | -5.48M | -6.47M | -8.14M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.39 | -0.62 | 10.86 | -2.36 | -2.60 | -1.92 | -5.17 | -3.39 | -4.92 | -5.05 | -27.66 | -7.50 |
| EPS (Diluted) | -0.39 | -0.62 | 10.86 | -2.36 | -2.60 | -1.92 | -5.17 | -3.39 | -4.92 | -5.05 | -27.66 | -7.50 |
| Shares Outstanding (Basic) | 61.12M | 34.30M | — | 1.33M | 1.32M | 1.32M | — | 1.14M | 1.08M | 1.08M | — | 1.08M |
| Shares Outstanding (Diluted) | 61.12M | 34.30M | — | 1.33M | 1.32M | 1.32M | — | 1.14M | 1.08M | 1.08M | — | 1.08M |
| EBITDA | -34.99M | -30.81M | -201.69M | -3.15M | -3.42M | -2.59M | -7.10M | -3.83M | -5.57M | -5.74M | -6.65M | -8.37M |
This table shows 12 quarterly periods of Damora Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow DMRA's reporting calendar. What is a income statement?